Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:50933 |
Name | ovarian serous carcinoma |
Definition | An ovarian carcinoma that has_material_basis_in the lining of the ovary and produces a serum-like fluid. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma ovarian serous carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Carboplatin + Torkinib | ovarian serous carcinoma | not applicable | detail... |
Unknown unknown | CFI-402257 | ovarian serous carcinoma | not applicable | detail... |
Unknown unknown | Paclitaxel + Vistusertib | ovarian serous carcinoma | not applicable | detail... |
MAP2K1 Q56_V60del | Selumetinib | ovarian serous carcinoma | predicted - sensitive | detail... |
BRAF V600E | BGB-283 | ovarian serous carcinoma | predicted - sensitive | detail... |
Unknown unknown | Berzosertib + Gemcitabine | ovarian serous carcinoma | not applicable | detail... |
BRAF V600E | Trametinib | ovarian serous carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02364713 | Phase II | Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Recruiting | USA | 0 |
NCT02446600 | Phase III | Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin | Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 2 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | 1 |
NCT02759588 | Phase Ib/II | GL-ONC1 | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02898207 | Phase I | Olaparib + Onalespib | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02983799 | Phase II | Olaparib | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | Completed | USA | CAN | 0 |
NCT03042702 | Phase II | thioureidobutyronitrile | A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer | Completed | USA | 0 |
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | 1 |
NCT03205176 | Phase I | AZD5153 | Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas | Active, not recruiting | USA | CAN | 0 |
NCT03402841 | Phase III | Olaparib | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION) | Active, not recruiting | CAN | 17 |
NCT03414047 | Phase II | Prexasertib | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | Active, not recruiting | USA | 7 |
NCT03462342 | Phase II | AZD6738 + Olaparib | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) | Recruiting | USA | 0 |
NCT03531645 | Phase II | Fulvestrant + Palbociclib | Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma | Recruiting | USA | 0 |
NCT03587311 | Phase II | Anetumab ravtansine + Bevacizumab Bevacizumab + Paclitaxel | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | CAN | 0 |
NCT03602859 | Phase III | Dostarlimab + Niraparib Niraparib | A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) | Active, not recruiting | USA | CAN | 17 |
NCT03673124 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole Treatment in Ovarian Cancer | Recruiting | USA | 0 |
NCT03695380 | Phase I | Atezolizumab + Cobimetinib + Niraparib Cobimetinib + Niraparib | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | Recruiting | USA | 3 |
NCT03840200 | Phase Ib/II | Ipatasertib + Rucaparib | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | Active, not recruiting | USA | 4 |
NCT03909152 | Phase II | Onapristone | A Study of Onapristone ER in Low Grade Serous Ovarian Cancer and Other Progesterone Receptor Positive Gynecologic Cancers | Recruiting | USA | 0 |
NCT03955471 | Phase II | Dostarlimab + Niraparib | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE) | Suspended | USA | 0 |
NCT04034927 | Phase II | Olaparib Olaparib + Tremelimumab | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | Suspended | USA | 0 |
NCT04092270 | Phase I | MSC2490484A + Pegylated liposomal-doxorubicin | A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients | Recruiting | USA | 0 |
NCT04095364 | Phase III | Carboplatin + Letrozole + Paclitaxel Letrozole | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer | Recruiting | USA | 1 |
NCT04209855 | Phase III | Paclitaxel Pegylated liposomal-doxorubicin Mirvetuximab Soravtansine Topotecan | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) | Recruiting | USA | CAN | 10 |
NCT04293094 | Phase I | AMG 650 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 3 |
NCT04296890 | Phase III | Mirvetuximab Soravtansine | A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (SORAYA) | Recruiting | USA | 9 |
NCT04315233 | Phase I | Belinostat + Ribociclib | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) | Recruiting | USA | 0 |
NCT04374630 | Phase II | Afuresertib + Paclitaxel Paclitaxel | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II) | Recruiting | USA | 0 |
NCT04421963 | Phase III | Olaparib | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O) | Recruiting | USA | CAN | 7 |
NCT04510584 | Phase II | Atezolizumab + Bevacizumab | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Not yet recruiting | CAN | 0 |
NCT04586335 | Phase I | CYH33 + Olaparib | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Recruiting | USA | 1 |
NCT04625270 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | Recruiting | USA | 0 |
NCT04669002 | Phase II | CRLX101 + Olaparib | EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | Recruiting | USA | 0 |
NCT04703920 | Phase I | Belinostat + Talazoparib | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | Not yet recruiting | USA | 0 |